Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES IPCA LABS ALKEM LABORATORIES/
IPCA LABS
 
P/E (TTM) x 25.0 27.4 91.3% View Chart
P/BV x 6.0 8.5 70.6% View Chart
Dividend Yield % 0.8 0.1 567.1%  

Financials

 ALKEM LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
IPCA LABS
Mar-19
ALKEM LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,7201,042 261.0%   
Low Rs1,660590 281.4%   
Sales per share (Unadj.) Rs697.9298.6 233.7%  
Earnings per share (Unadj.) Rs96.135.0 274.6%  
Cash flow per share (Unadj.) Rs117.349.4 237.2%  
Dividends per share (Unadj.) Rs25.003.00 833.3%  
Dividend yield (eoy) %1.10.4 310.5%  
Book value per share (Unadj.) Rs515.2247.1 208.5%  
Shares outstanding (eoy) m119.57126.35 94.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.12.7 114.8%   
Avg P/E ratio x22.823.3 97.7%  
P/CF ratio (eoy) x18.716.5 113.2%  
Price / Book Value ratio x4.33.3 128.7%  
Dividend payout %26.08.6 303.4%   
Avg Mkt Cap Rs m261,879103,108 254.0%   
No. of employees `00014.313.4 106.6%   
Total wages/salary Rs m15,0557,874 191.2%   
Avg. sales/employee Rs Th5,822.62,807.0 207.4%   
Avg. wages/employee Rs Th1,050.5585.8 179.3%   
Avg. net profit/employee Rs Th802.0329.0 243.8%   
INCOME DATA
Net Sales Rs m83,44437,732 221.1%  
Other income Rs m1,042577 180.7%   
Total revenues Rs m84,48638,309 220.5%   
Gross profit Rs m14,7346,901 213.5%  
Depreciation Rs m2,5281,824 138.6%   
Interest Rs m651189 344.8%   
Profit before tax Rs m12,5985,465 230.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1051,042 106.0%   
Profit after tax Rs m11,4934,422 259.9%  
Gross profit margin %17.718.3 96.5%  
Effective tax rate %8.819.1 46.0%   
Net profit margin %13.811.7 117.5%  
BALANCE SHEET DATA
Current assets Rs m54,96023,778 231.1%   
Current liabilities Rs m32,43310,975 295.5%   
Net working cap to sales %27.033.9 79.6%  
Current ratio x1.72.2 78.2%  
Inventory Days Days80104 76.7%  
Debtors Days Days7266 109.4%  
Net fixed assets Rs m32,71020,368 160.6%   
Share capital Rs m239253 94.6%   
"Free" reserves Rs m61,36830,971 198.1%   
Net worth Rs m61,60731,224 197.3%   
Long term debt Rs m1,5921,409 113.1%   
Total assets Rs m99,43345,507 218.5%  
Interest coverage x20.430.0 68.0%   
Debt to equity ratio x00 57.3%  
Sales to assets ratio x0.80.8 101.2%   
Return on assets %12.210.1 120.5%  
Return on equity %18.714.2 131.7%  
Return on capital %21.017.3 121.0%  
Exports to sales %19.145.9 41.6%   
Imports to sales %3.016.6 17.9%   
Exports (fob) Rs m15,91717,308 92.0%   
Imports (cif) Rs m2,4836,266 39.6%   
Fx inflow Rs m16,06117,308 92.8%   
Fx outflow Rs m2,4836,266 39.6%   
Net fx Rs m13,57811,042 123.0%   
CASH FLOW
From Operations Rs m5,8514,923 118.9%  
From Investments Rs m-7,414-1,563 474.3%  
From Financial Activity Rs m792-1,832 -43.2%  
Net Cashflow Rs m-7311,528 -47.9%  

Share Holding

Indian Promoters % 66.9 45.9 145.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 11.4 290.4%  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.4 -  
Shareholders   68,381 36,892 185.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - TTK HEALTHCARE COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS